Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,588.19
(
-0.28%
)
US TECH 100
23,648.00
(
-0.31%
)
Dow Jones
46,003.11
(
-0.04%
)
Brent Oil
105.66
(
1.17%
)
Bitcoin
70,257.00
(
0.51%
)
News Focus
News Focus
Post# of 257262
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122802
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: JohnWayne post# 204556

Friday, 01/27/2017 10:44:22 AM

Friday, January 27, 2017 10:44:22 AM

Post# of 257262
CHMP approves AMGN’s Humira FoB under two brand names—Amgevita (with a “g”) and Solymbic:

http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2017/01/news_detail_002682.jsp&mid=WC0b01ac058004d5c1

http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500220219
http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500220220

Amgevita and Solymbic are the same drug, but Solymbic lacks approval for pediatric indications. I don’t know the reason for using dual EU brand names for AMGN’s Humira FoB; if anyone reading this does know, please post.

Note: AMGN’s Humira FoB for the US market is Amjevita (with a “j”): #msg-125359509, #msg-126114458.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today